Assessment of nonsteroidal anti-inflammatory drug-induced cardiotoxicity

Expert Opinion on Drug Metabolism and Toxicology

Volumn 10, Issue 2, 2014, Pages 143-156

  Singh, Bhulan Kumar ^a   Haque, Syed Ehtaishamul ^b   Pillai, Krishna Kolappa ^b  

^a KRISHNA INSTITUTE OF ENGINEERING AND TECHNOLOGY   (India)

^b HAMDARD UNIVERSITY   (India)

Author keywords

Adenomas; Arthritis; Cardiotoxicity; Cyclooxygenase; Nonsteroidal anti inflammatory drugs; Prostacyclin; Reactive oxygen species

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG EFFECT; DRUG SAFETY; ELEVATED BLOOD PRESSURE; ENDOTHELIAL DYSFUNCTION; HUMAN; NONHUMAN; OXIDATIVE STRESS; PAIN; PROSTAGLANDIN SYNTHESIS; REVIEW; RHEUMATIC DISEASE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS; CARDIOTOXINS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS;

EID: 84892703427     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2014.856881     Document Type: Review

References (94)

1. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284: 1247-55
2. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR Study Group. N Engl J Med 2000;343: 1520-8
3. Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004;364: 665-74
4. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352: 1092-102
5. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352: 1071-80
6. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352: 1081-91
7. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal antiinflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332: 1302-8
8. Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013;382: 769-79
9. García Rodríguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008;52: 1628-36
10. McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of populationbased controlled observational studies. PLoS Med 2011;8:e1001098
11. White WB, Cruz C. Impact of NSAIDs on cardiovascular risk and hypertension. Italian J Med 2011;5: 175-83
12. García Rodríguez LA, González-Pérez A, Bueno H, Hwa J. NSAID use selectively increases the risk of non-fatal myocardial infarction: a systematic review of randomised trials and observational studies. PLoS ONE 2011;6:e16780
13. Fosbol EL, Gislason GH, Jacobsen S, et al. Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDS) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther 2009;85: 190-7
14. Olsen AS, Fosbøl EL, Lindhardsen J, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction. A nationwide cohort study. Circulation 2011;123: 2226-35
15. Ruana CH, Sob SP, Ruanb KH. Inducible COX-2 dominates over COX- 1 in prostacyclin biosynthesis: mechanisms of COX-2 inhibitor risk to heart disease. Life Sci 2011;88: 24-30
16. Kirkby NS, Lundberg MH, Harrington LS, et al. Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system. Proc Natl Acad Sci USA 2012;109: 17597-602
17. Pietro Minuz P. Nonsteroidal antiinflammatory drugs and cardiovascular risk. Is prostacyclin inhibition the key event? J Am Coll Cardiol 2008;52: 1637-9
18. Rudic RD, Brinster D, Cheng Y, et al. COX-2-derived prostacyclin modulates vascular remodeling. Circ Res 2005;96: 1240-7
19. Egan KM, Wang M, Fries S, et al. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 2005;111: 334-42
20. Rabausch K, Bretschneider E, Sarbia M, et al. Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX-2-derived prostaglandins. Circ Res 2005;96:e1-6
21. Bolli R, Shinmura K, Tang XL, et al. Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc Res 2002;55: 506-19
22. Antman EM, DeMets D, Loscalzo J. Cyclooxygenase inhibition and cardiovascular risk. Circulation 2005;112: 759-70
23. Singh BK, Pillai KK, Haque SE, Dubey K. Diclofenac sodium, a nonselective nonsteroidal antiinflammatory drug aggravates doxorubicin-induced cardiomyopathy in rats. J Cardiovasc Pharmacol 2010;55: 139-44
24. Oitate M, Hirota T, Takahashi M, et al. Mechanism for covalent binding of rofecoxib to elastin of rat aorta. J Pharmacol Exp Ther 2007;320: 1195-203
25. Virdis A, Colucci R, Fornai M, et al. Cyclooxygenase-2 inhibition improves vascular endothelial dysfunction in a rat model of endotoxic shock: role of inducible nitric-oxide synthase and oxidative stress. J Pharmacol Exp Ther 2005;312: 945-53
26. Steffel J, Hermann M, Greutert H, et al. Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation. Circulation 2005;111: 1685-9
27. Aronoff DM, Oates JA, Boutaud O. New insights into the mechanism of action of acetaminophen: its clinical pharmacologic characteristics reflect its inhibition of the two prostaglandin H2 synthases. Clin Pharmacol Ther 2006;79: 9-19
28. Wheal AJ, Bennett T, Randall MD, Gardiner SM. Cardiovascular effects of cannabinoids in conscious spontaneously hypertensive rats. Br J Pharmacol 2007;152: 717-24
29. Sudano I, Flammer AJ, Périat D, et al. Acetaminophen increases blood pressure in patients with coronary artery disease. Circulation 2010;122: 1789-96
30. Sudano I, Flammer AJ, Roas S, et al. Nonsteroidal anti-inflammatory drugs, acetaminophen, and hypertension. Curr Hypertens Rep 2012;14: 304-9
31. Gualtierotti R, Zoppi A, Mugellini A, et al. Effect of naproxen and acetaminophen on blood pressure lowering by ramipril, valsartan andaliskiren in hypertensive patients. Expert Opin Pharmacother 2013;14: 1875-84
32. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004;351: 1709-11
33. Moreno-Sánchez R, Bravo C, Vásquez C, et al. Inhibition and uncoupling of oxidative phosphorylation by nonsteroidal anti-inflammatory drugs: study in mitochondria, submitochondrial particles, cells, and whole heart. Biochem Pharmacol 1999;57: 743-52
34. Cocco T, Di Paola M, Papa S, Lorusso M. Arachidonic acid interaction with the mitochondrial electron transport chain promotes reactive oxygen species generation. Free Radic Biol Med 1999;27: 51-9
35. Sowers JR, White WB, Pitt B, et al. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-h blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 2005;165: 161-8
36. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994;121: 289-300
37. Aw TJ, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005;165: 490-6
38. Morgan TO, Anderson A, Bertram D. Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril. Am J Hypertens 2000;13: 1161-7
39. Wang D, Patel VV, Ricciotti E, et al. Cardiomyocyte cyclooxygenase-2 influences cardiac rhythm and function. Proc Natl Acad Sci USA 2009;106: 7548-52
40. Whelton A, Schulman G, Wallemark C, et al. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 2000;160: 1465-70
41. Vega J, Goecke H, Méndez GP, Guarda FJ. Nephrotic syndrome and acute tubular necrosis due to meloxicam use. Ren Fail 2012;34: 1344-7
42. Schwartz JI, Vandormael K, Malice MP, et al. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clin Pharmacol Ther 2002;72: 50-61
43. Qi Z, Cai H, Morrow JD, Breyer MD. Differentiation of cyclooxygenase 1- and 2-derived prostanoids in mouse kidney and aorta. Hypertension 2006;48: 323-8
44. Knights KM, Winner LK, Elliot DJ, et al. Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDPglucuronosyltransferases: inhibition by NSAIDs. Br J Clin Pharmacol 2009;68: 402-12
45. Krum H, Swergold G, Gammaitoni A, et al. Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs. Cardiovasc Ther 2012;30: 342-50
46. White WB, Kent J, Taylor A, et al. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension 2002;39: 929-34
47. Izhar M, Alausa T, Folker A, et al. Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics. Hypertension 2004;43: 573-7
48. Whelton A, White WB, Bello AE, et al. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 2002;90: 959-63
49. Houston MC, Weir M, Gray J, et al. The effects of nonsteroidal antiinflammatory drugs on blood pressures of patients with hypertension controlled by verapamil. Arch Intern Med 1995;155: 1049-54
50. White WB, Schnitzer TJ, Bakris GL, et al. Effects of naproxcinod on blood pressure in patients with osteoarthritis. Am J Cardiol 2011;107: 1338-45
51. Townsend R, Bittar N, Rosen J, et al. Blood pressure effects of naproxcinod in hypertensive patients. J Clin Hypertens (Greenwich) 2011;13: 376-84
52. Food and Drug Administration. Center for Drug Evaluation and Research. Joint Meeting of the Arthritis Advisory Committee (AAC) and the Drug Safety and Risk Management Advisory Committee (DSaRM), 2010 FDA Web site: spaulding, M.D., M.P.H. Available from: http://www.fda.gov/downloads/ advisorycommittees/ committeesmeetingmaterials/drugs/ arthritisadvisorycommittee/ucm212680. pdf [Accessed on 12 October 2013]
53. Baerwald C, Verdecchia P, Duquesroix B, et al. Efficacy, safety, and effects on blood pressure of naproxcinod 750 mg twice daily compared with placebo and naproxen 500 mg twice daily in patients with osteoarthritis of the hip: a randomized, double-blind, parallelgroup, multicenter study. Arthritis Rheum 2010;62: 3635-44
54. White WB, Faich G, Whelton A, et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002;89: 425-30
55. Farkouh ME, Kirshner H, Harrington RA, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004;364: 675-84
56. Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006;368: 1771-81
57. Chan FK, Lanas A, Scheiman J, et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010;376: 173-09
58. Cryer B, Li C, Simon LS, et al. GIREASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial. Am J Gastroenterol 2013;108: 392-400
59. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355: 873-84
60. Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006;355: 885-95
61. Solomon SD, Pfeffer MA, McMurray JJ, et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 2006;114: 1028-35
62. ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials 2006;1:e33
63. Kerr DJ, Dunn JA, Langman MJ, et al. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N Engl J Med 2007;357: 360-9
64. Pathan RA, Singh BK, Pillai KK, Dubey K. Naproxen aggravates doxorubicin-induced cardiomyopathy in rats. Indian J Pharmacol 2010;42: 44-9
65. Dowd NP, Scully M, Adderley SR, et al. Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J Clin Invest 2001;108: 585-90
66. Zaitone SA, Moustafa YM, Mosaad SM, El-Orabi NF. Effect of evening primrose oil and omega-3 polyunsaturated fatty acids on the cardiovascular risk of celecoxib in rats. J Cardiovasc Pharmacol 2011;58: 72-9
67. Li H, Hortmann M, Daiber A, et al. Cyclooxygenase 2-selective and nonselective nonsteroidal antiinflammatory drugs induce oxidative stress by up-regulating vascular NADPH oxidases. J Pharmacol Exp Ther 2008;326: 745-53
68. Schjerning Olsen AM, Fosbøl EL, Lindhardsen J, et al. Duration of treatment with nonsteroidal antiinflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation 2011;123: 2226-35
69. Fosbøl EL, Folke F, Jacobsen S, et al. Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals. Circ Cardiovasc Qual Outcomes 2010;3: 395-405
70. Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal antiinflammatory drugs in chronic heart failure. Arch Intern Med 2009;169: 141-9
71. Ray WA, Varas-Lorenzo C, Chung CP, et al. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes 2009;2: 155-63
72. Roumie CL, Choma NN, Kaltenbach L, et al. Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease. Pharmacoepidemiol Drug Saf 2009;18: 1053-63
73. Hammad TA, Graham DJ, Staffa JA, et al. Onset of acute myocardial infarction after use of non-steroidal antiinflammatory drugs. Pharmacoepidemiol Drug Saf 2008;17: 315-21
74. van Staa TP, Rietbrock S, Setakis E, Leufkens HG. Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction? J Intern Med 2008;264: 481-92
75. Chan AT, Manson JE, Albert CM, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006;113: 1578-87
76. Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 2006;113: 2906-13
77. Solomon DH, Avorn J, Stürmer T, et al. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum 2006;54: 1378-89
78. Ray WA, Stein CM, Hall K, et al. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002;359: 118-23
79. van der Linden MW, van der Bij S, Welsing P, et al. The balance between severe cardiovascular and gastrointestinal events among users of selective and nonselective non-steroidal anti-inflammatory drugs. Ann Rheum Dis 2009;68: 668-73
80. Jick SS, Kaye JA, Jick H. Diclofenac and acute myocardial infarction in patients with no major risk factors. Br J Clin Pharmacol 2007;64: 662-7
81. Hudson M, Rahme E, Richard H, Pilote L. Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective cyclooxygenase 2 inhibitors: a class effect? Arthritis Rheum 2007;57: 516-23
82. Andersohn F, Suissa S, Garbe E. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Circulation 2006;113: 1950-7
83. Helin-Salmivaara A, Virtanen A, Vesalainen R, et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J 2006;27: 1657-63
84. McGettigan P, Han P, Henry D. Cyclooxygenase-2 inhibitors and coronary occlusion-exploring doseresponse relationships. Br J Clin Pharmacol 2006;62: 358-65
85. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006;296: 1633-44
86. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and nonselective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005;365: 475-81
87. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal antiinflammatory drugs: population based nested case-control analysis. BMJ 2005;330:1366
88. Johnsen SP, Larsson H, Tarone RE, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 2005;165: 978-84
89. García Rodríguez LA, Varas-Lorenzo C, Maguire A, González-Pérez A. Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation 2004;109: 3000-6
90. White WB, Campbell P. Blood pressure destabilization on nonsteroidal antiinflammatory agents: acetaminophen exposed? Circulation 2010;122: 1779-81
91. Curhan GC, Willett WC, Rosner B, Stampfer MJ. Frequency of analgesic use and risk of hypertension in younger women. Arch Intern Med 2002;162: 2204-8
92. Forman JP, Stampfer MJ, Curhan GC. Non-narcotic analgesic dose and risk of incident hypertension in US women. Hypertension 2005;46: 500-7
93. Forman JP, Rimm EB, Curhan GC. Frequency of analgesic use and risk of hypertension among men. Arch Intern Med 2007;167: 394-09
94. Dawson J, Fulton R, McInnes GT, et al. Acetaminophen use and change in blood pressure in a hypertensive population. J Hypertens 2013;31: 1485-90